In our study, the patient group had a level of adropin significantly lower than the control group (P < .001), which may lead us to the fact that adropin deficiency may promote inflammation and neurodegeneration in the CNS and/or contribute to the formation of MS. This evidence concerns the gene ENHO and myeloid sarcoma.